Continued Versus Interrupted Oral Anticoagulation During Transfemoral Transcatheter Aortic Valve Implantation and Impact of Postoperative Anticoagulant Management on Outcome in Patients With Atrial Fibrillation.
Administration, Oral
Aged
Aged, 80 and over
Anticoagulants
/ administration & dosage
Aortic Valve Stenosis
/ complications
Atrial Fibrillation
/ complications
Blood Coagulation
Drug Administration Schedule
Female
Follow-Up Studies
Germany
/ epidemiology
Humans
Incidence
Intraoperative Period
Male
Postoperative Period
Retrospective Studies
Risk Assessment
/ methods
Risk Factors
Stroke
/ epidemiology
Survival Rate
/ trends
Transcatheter Aortic Valve Replacement
Treatment Outcome
Journal
The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277
Informations de publication
Date de publication:
01 04 2019
01 04 2019
Historique:
received:
22
09
2018
revised:
20
12
2018
accepted:
26
12
2018
pubmed:
20
1
2019
medline:
10
1
2020
entrez:
20
1
2019
Statut:
ppublish
Résumé
The role of continued versus interrupted oral anticoagulation (OAC) in patients with atrial fibrillation (AF) who underwent transfemoral transcatheter aortic valve implantation (TF-TAVI) for severe aortic stenosis is uncertain. The aim of this retrospective investigation was to evaluate the impact (1) of continued versus interrupted OAC on early safety and (2) of postoperative anticoagulant management on the 1-year mortality in patients with AF who underwent TF-TAVI. Consecutive patients with AF and on OAC at admission (n = 598) were stratified according to interrupted (iVKA) versus continued vitamin K antagonist (cVKA) versus continued direct oral anticoagulants (DOAC) at the time of TF-TAVI. Valve Academic Research Consortium-2 early safety was the primary outcome measure. Patients with iVKA (n = 299), cVKA (n = 117), and DOAC (n = 182) had comparable baseline characteristics including age (p = 0.25), gender (p = 0.33), and STS-Score (p = 0.072). The proportion of patients having a CHA
Identifiants
pubmed: 30658919
pii: S0002-9149(19)30045-1
doi: 10.1016/j.amjcard.2018.12.042
pii:
doi:
Substances chimiques
Anticoagulants
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1134-1141Informations de copyright
Copyright © 2019. Published by Elsevier Inc.